- 45-0036-42 - Invitrogen Antibodies CD247 antibody

Submitted references Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.

Cha JH, Chan LC, Wang YN, Chu YY, Wang CH, Lee HH, Xia W, Shyu WC, Liu SP, Yao J, Chang CW, Cheng FR, Liu J, Lim SO, Hsu JL, Yang WH, Hortobagyi GN, Lin C, Yang L, Yu D, Jeng LB, Hung MC
The Journal of biological chemistry 2022 Apr;298(4):101817

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment.

Kim YD, Park SM, Ha HC, Lee AR, Won H, Cha H, Cho S, Cho JM
Journal of Cancer 2020;11(14):4059-4072

Synthetic Abortive HIV-1 RNAs Induce Potent Antiviral Immunity.

Stunnenberg M, Sprokholt JK, van Hamme JL, Kaptein TM, Zijlstra-Willems EM, Gringhuis SI, Geijtenbeek TBH
Frontiers in immunology 2020;11:8

Subclinical Cytomegalovirus DNA Is Associated with CD4 T Cell Activation and Impaired CD8 T Cell CD107a Expression in People Living with HIV despite Early Antiretroviral Therapy.

Christensen-Quick A, Massanella M, Frick A, Rawlings SA, Spina C, Vargas-Meneses M, Schrier R, Nakazawa M, Anderson C, Gianella S
Journal of virology 2019 Jul 1;93(13)

Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.

Choi JW, Lee ES, Kim SY, Park SI, Oh S, Kang JH, Ryu HA, Lee S
BMC cancer 2019 Aug 19;19(1):817

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.

Guo X, Jiang H, Shi B, Zhou M, Zhang H, Shi Z, Du G, Luo H, Wu X, Wang Y, Sun R, Li Z
Frontiers in pharmacology 2018;9:1118

Psoriasis patients demonstrate HLA-Cw*06:02 allele dosage-dependent T cell proliferation when treated with hair follicle-derived keratin 17 protein.

Yunusbaeva M, Valiev R, Bilalov F, Sultanova Z, Sharipova L, Yunusbayev B
Scientific reports 2018 Apr 17;8(1):6098

Differences in Peripheral Blood Lymphocytes between Brand-Name and Generic Tacrolimus Used in Stable Liver Transplant Recipients.

Kim JM, Kwon CHD, Joh JW, Sinn DH, Choi GS, Park JB, Kang ES, Lee SK
Medical principles and practice : international journal of the Kuwait University, Health Science Centre 2017;26(3):221-228

CCL20 Secretion from the Nucleus Pulposus Improves the Recruitment of CCR6-Expressing Th17 Cells to Degenerated IVD Tissues.

Zhang W, Nie L, Wang Y, Wang XP, Zhao H, Dongol S, Maharjan S, Cheng L
PloS one 2013;8(6):e66286

A monoclonal antibody selection for immunohistochemical examination of lymphoid tissues from non-human primates.

Kap YS, van Meurs M, van Driel N, Koopman G, Melief MJ, Brok HP, Laman JD, 't Hart BA
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2009 Dec;57(12):1159-67

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Staining of normal human peripheral blood cells with Mouse IgG1 K Isotype Control PerCP-Cyanine5-5 (Product # 45-4714-82) (blue histogram) or Anti-Human CD3 PerCP-Cyanine5-5 (purple histogram). Cells in the lymphocyte gate were used for analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Circulating percentages of Th17 cells and CCR6-positive cells in peripheral blood are increased in IVD degenerated patients when compared with controls. Heparinized peripheral whole blood cells from 20 patients and 15 healthy controls were stimulated with phorbol myristate acetate (PMA), ionomycin, and monensin for 4 h and subsequently stained with fluorochrome-labeled antibodies as described in Materials and Methods. A(a) Lymphocytes were gated by flow cytometry. A(b) CD3 + T subsets were gated by flow cytometry; the plots in the inset box represent the CD3 + T cells. A(c) Representative IL-17 expression levels in the CD3 + CD8 - T subsets (CD4 + T subsets) from each group are shown. The percentages of positive cells are shown in the upper left panels. A(d) Representative surface CCR6 expression levels on the CD3 + CD8 - IL-17 + subsets from each group are shown. The percentages of positive cells are shown in the right panel. (B) The percentage of circulating Th17 cells was significantly higher in IVD degenerated patients (2.973+-0.689%) than in the control group (1.039+-0.156%; *, p

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 In vitro T cell proliferation. Mononuclear cells from psoriatic patients (red curve) and healthy controls (blue curve) were labelled with 1 uM CFSE prior to culturing and incubated for 5 days alone, with 1 ug/ml PHA ( A ) or in the presence of recombinant proteins K17 ( B ), S1 ( C ), S4 ( D ), PS1 ( E ) and PK ( F ) at concentration of 10 ug/ml. After 5 days, cells were labelled with a PE-conjugated anti-CD3 antibody and 7-AAD prior to flow cytometry analysis. Gated CD3+ lymphocytes are shown on the CFSE fluorescence histograms to demonstrate the decrease in fluorescence intensity during divisions. The higher peak for both patients and healthy controls represents a larger population of non-dividing parental cells (P). The signal of interest is the smaller peak that corresponds to dividing cells (shown using arrow under F ), and such cells are only observed in patents when treated with K17 ( B ), S1 ( C ), or S4 ( D ) proteins. Figures represent the percentage of CFSE low CD3+ cells (proliferating population).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 2 Expression of PD-L1 on human HCC PLC/PRF/5 cells. (A) Human HCC PLC/PRF/5 cells were cultured alone in the absence of GPC3-CAR T cells in RPMI 1640 medium containing 10% FBS. (B) Human HCC PLC/PRF/5 cells were cocultured with GPC3-CAR T cells at an effector:Target ratio of 1:1 for 18 h in RPMI 1640 medium containing 10% FBS. PD-L1 was determined by flow cytometry in the CD3-negative gate, and the fixable, viable stain 780 was used for discriminating live from dead cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: FIGURE 4 Efficient disruption of PD-1 expression on the surface of GPC3-CAR T cells. PD-1 and CAR expression on the surface of T cells were detected by flow cytometry on day 3 after the re-stimulation with anti-CD3/anti-CD28 beads. UTD, untransduced T cells; WT, wild type.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 Identification of key immune cell types of MYJ1633 following ex vivo expansion. a The distribution of NK cells (CD3 - CD16 + CD56 + ), NKT cells (CD3 + CD16 + CD56 + ), and T cells (CD3 + CD16 - CD56 - ) of freshly isolated PBMCs and MYJ1633 was examined by flow cytometry. b Proportion of helper T cells (Th cells; CD4 + ) and cytotoxic T cells (Tc cells; CD8 + ) among CD3 + cells of MYJ1633. These data were analyzed from 6 individuals (Additional file 1 : Figure S1). Significant differences between groups were determined by Student's t test. The data represented as mean +- SEM

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 HIV-1 Cap-RNA 58 -treated DCs mediate T cell proliferation and differentiation. DCs were unstimulated or treated with 1 nM HIV-1 Cap-RNA 58 or LPS for 48 h, cocultured with CellTrace Violet-labeled peripheral blood lymphocytes and harvested after 5 days. Proliferation was determined in (A) live CD3 + CD4 + cells and (B) CD3 + CD8 + T cells by flow cytometry. (C,D) DCs were treated with vehicle control, 1 nM HIV-1 control RNA, 1 nM HIV-1 Cap-RNA 58 , LPS, LPS + PGE 2 , or LPS + IFNgamma for 48 h and cocultured with naive T cells. After 11-13 days, cells were restimulated and intracellular expression levels of IFNgamma (T H 1) and IL-4 (T H 2) were analyzed using flow cytometry. Number in plots indicate percentage of cells in the quadrant. Data are representative of collated data of three (A,B) or four (D) donors, or four donors (C) of different experiments (mean +- s.d.). * P < 0.05, ** P < 0.01, Student's t -test. NS, not significant.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 CG-745 increases helper T cells, cytotoxic T cells and natural killer T cells, and decreases Treg: (A) hPBMCs were incubated with CG (CG-745) for 36 hours and a subset of hPBMCs was analyzed using the antibodies indicated in the text; (B) hPBMCs were co-cultured with Huh7, Hep3B, HepG2 or PLC/PRF/5 cells for 36 hours with or without CG, and a subset of hPBMCs was analyzed by Attune Nxt (Invitrogen, USA).

45-0036-42

Antibody data